Multiple Myeloma Clinical Trial
A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat
Summary
This study aims to describe current treatment patterns in the real-world setting among patients with multiple myeloma who are initiating treatment with (or changing treatment to) panobinostat and explore the associations with baseline patient characteristics, healthcare resource utilization, and clinical outcomes.
Eligibility Criteria
Inclusion Criteria:
Willing and able to provide written informed consent
At least 18 years of age
Clinical diagnosis of multiple myeloma that meets published diagnostic criteria
Initiating panobinostat within 60 days of enrollment
ECOG performance status 0-1
Availability of documentation from the patient's medical records regarding previous myeloma treatment, response, and duration of response
Willing and able to complete the PRO questionnaire
Exclusion Criteria:
Diagnosed with any B-cell malignancy other than myeloma
Estimated life expectancy <6 months
Currently enrolled in any interventional clinical trial at study entry (note: patients who enroll in an interventional clinical trial after enrollment may remain in the registry)
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 7 Locations for this study
Indianapolis Indiana, 46260, United States
Las Vegas Nevada, 89106, United States
Charlotte North Carolina, 28204, United States
Huntersville North Carolina, 28078, United States
Gettysburg Pennsylvania, 17325, United States
Myrtle Beach South Carolina, 29572, United States
Rock Hill South Carolina, 29732, United States
How clear is this clinincal trial information?